Our Alliances

  • Lundbeck Logo

    Otsuka has a long term global alliance agreement with the Danish company, Lundbeck, with whom we share a heritage of research and development in neuroscience. We believe that this collaboration will lead to new products that will have a positive impact on a broad range of mental health illnesses and hence improve the lives of millions of people.

  • Bristol-Myers Squibb Logo
    Bristol-Myers Squibb

    Otsuka is a collaborative partner of Bristol-Myers in the commercialization of a treatment for chronic myeloid leukemia in the United States, Japan, and several European countries.

  • GW Pharmaceuticals logo
    GW Pharmaceuticals

    Otsuka has been collaborating with U.K. biotech company, GW Pharmaceuticals, on the U.S. development of a drug to treat advanced cancer pain. The drug is currently in Phase III trials. If successful, GW has granted Otsuka an exclusive license to market the treatment in the U.S.

  • Proteus Digital Health

    Otsuka is collaborating with Proteus Digital Health, Inc., based in California, on the development and commercialization of cutting-edge wearable and ingestible technologies. A result of this collaboration is the world’s first advancement in technology-enabled medicine, the ABILIFY MYCITE System, approved by the U.S. Food and Drug Administration in October 2017.The aim is to help patients better manage their conditions and to help clinicians provide more effective care. This new frontier science is in keeping with our philosophy: ‘Otsuka-people creating new products for better health worldwide’.

  • Akebia

    In December 2016, Otsuka Pharmaceutical Co., Ltd. entered into a co-development agreement with Akebia Therapeutics, Inc. to share equally in the development and commercialization of vadadustat in the United States. Vadadustat, is an investigational drug in a new class of oral hypoxia-inducible factor (HIF) stabilizers. Vadadustat is currently in development as a potential treatment for anemia associated with chronic kidney disease (CKD). Otsuka expanded its collaboration with Akebia through a license agreement covering commercialization of vadadustat, once approved, in Europe, China, Russia, Canada, Australia, the Middle East and certain other territories.

  • Click Therapeutics

    Otsuka is collaborating with Click Therapeutics to develop and commercialize a prescription digital therapeutic for the treatment of major depressive disorder (MDD). The collaboraton will leverage Click’s demonstrated ability to discover and validate a software application and deploy it commercially and Otsuka’s expertise in developing approved prescription therapies for patients with serious mental illnesses, including Otsuka’s established development and commercialization capabilities. The companies believe digital therapeutics align naturally with psychiatry and have significant potential to transform mental healthcare.

Our Affiliates

  • Avanir logo
    Avanir Pharmaceuticals, Inc.

    Avanir Pharmaceuticals, Inc., a biopharmaceutical company focused on developing treatments for patients with central nervous system disorders. As well as producing the world’s first and only approved treatment for the neurologic disease pseudobulbar affect (PBA), Avanir has been working towards drugs for Alzheimer’s disease and Parkinson’s disease.

  • Astex logo
    Astex Pharmaceuticals, Inc.

    Otsuka’s commitment to cutting-edge science can be seen in our work with Astex Pharmaceuticals. The aim is to complement our research and development strengths with Astex’s fragment-based drug discovery technology, one of the most significant new drug discovery platforms in the last 20 years. This combination of skills shows great promise in bringing new therapies in neuroscience and oncology than was previously possible. Astex is a leader in innovative drug discovery and development, committed to the fight against cancer and diseases of the central nervous system. As part of Japan’s leading pharmaceutical company, Otsuka Pharmaceutical Co. Ltd., Astex operates from two sites with drug discovery research headquarters in Cambridge, UK and clinical development headquarters in Pleasanton, California, USA.

  • Visterra

    In 2018, Otsuka acquired Visterra, a clinical stage biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases. Its Hierotope® platform is comprised of novel and differentiated tools and technologies for the development of next-generation antibody-based therapies. Visterra’s pipeline includes programs targeting IgA nephropathy and other kidney diseases, cancer, chronic pain and infectious diseases. The extensive overlap in disease areas prioritized by both Otsuka and Visterra reflects a shared, deeper commitment to tackle the most difficult treatment challenges through innovative approaches.


Otsuka has been committed for more than 3 decades to developing novel drugs for neurological conditions.